New Trial Shows 62 Percent MASH Reversal with Semaglutide as $32 Billion Market Heats Up

In a major breakthrough published on April 30, 2025, in The New England Journal of Medicine, semaglutide has emerged as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH)—a severe liver condition formerly known as NASH. This Phase 3 clinical trial marks the first large-scale human study showing semaglutide’s significant benefit in reversing liver inflammation and scarring associated with the disease.

Semaglutide, a GLP-1 receptor agonist, was tested in a randomized, double-blind trial involving weekly 2.4 mg injections for 72 weeks. Participants, many of whom had type 2 diabetes and obesity, also received lifestyle counseling. Results were compelling: 62.9% achieved inflammation resolution, compared to 34.3% on placebo; fibrosis improved in 36.8%, versus 22.4% in the control group. Even more telling, 32.7% showed both improvements, double the placebo rate.

Beyond liver health, patients lost an average of 10.5% body weight—a stark contrast to the 2.0% reduction in the placebo group—and showed improved liver enzyme and fibrosis marker levels, highlighting semaglutide’s multi-system benefits.

MASH, a progressive form of fatty liver disease, affects over 1 billion people worldwide and is tightly linked with the rise of metabolic syndromes like obesity and diabetes. Left unchecked, it can escalate to cirrhosis, liver failure, or even liver cancer. Despite its prevalence, approved treatments remain extremely limited, with the first FDA-approved drug—resmetirom—only entering the market in March 2024.

The MASH drug development space is rapidly expanding, fueled by projections that the global market will reach $10.7 billion by 2025 and $32.2 billion by 2030, according to Frost & Sullivan. Multiple novel therapeutic classes are under investigation, including THR-β agonists, PPAR modulators, FXR activators, and FGF analogs. Four drugs, including TERN-501, VK2809, ASC41, and HSK31679, are currently in Phase 2 trials.

As GLP-1 analogs like semaglutide gain clinical validation, the competitive landscape intensifies. With a massive patient base and limited approved therapies, the race to dominate this high-stakes, high-reward market is officially underway.